Multi-kinase-IN-4 (compound 5d) is a multi-targeted kinase inhibitor active against VEGFR2, EGFR, HER2, and CDK2, with respective IC50 values of 0.33, 0.22, 0.18, and 2.09 μM. It exhibits broad-spectrum anti-cancer properties in HepG2, MCF-7, MDA-231, and HeLa cell lines, with IC50 values ranging from 1.94 to 7.1 µM, and demonstrates lower toxicity in WI-38 cells (IC50 = 40.85 µM). Additionally, it induces apoptosis and causes S-phase cell cycle arrest in HepG2 cells, and holds potential for cancer research [1].

VEGFR2:0.33 μM, CDK2:2.09 μM, HER2:0.18 mM

Multi-kinase-IN-4（化合物5d）(48小时)对HepG2、MCF-7、MDA-231和HeLa细胞株展现出明显的细胞毒性效应，其IC 50值分别为7.10、2.48、1.94和6.38 µM；相比之下，对WI38细胞的毒性作用较弱（IC 50 = 64.29 µM）[1]。在7.1 µM浓度和24小时处理后，Multi-kinase-IN-4导致HepG2细胞S期停滞增加9.23%，同时G0-G1期和G2/M期细胞百分比相应减少了4.50%与4.73% [1]。此外，相同条件下，Multi-kinase-IN-4引发的早期与晚期细胞凋亡以及坏死细胞比例达到7.51%、3.45%和3.08% [1]。